Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study
Tóm tắt
This study investigated the clinical and antimicrobial characteristics of Acinetobacter spp. bloodstream infection (BSI) in hematological patients. Risk factors for 30-day mortality and carbapenem-resistant Acinetobacter spp. (CRA) BSI acquisition were also identified. We reviewed forty hematological patients with Acinetobacter spp. BSI in a large Chinese blood disease hospital between 2013 and 2022. The remaining CRA isolates were subjected to whole-genome sequencing. The 30-day mortality rate was high at 35%. Hematological patients with Acinetobacter spp. BSI often presented with severe conditions and co-infections at multiple sites. All strains were colistin-susceptible and 40.0% were CR. Multivariate analysis identified several risk factors associated with CRA BSI acquisition, including previous exposure to carbapenems within 30 days and CRA colonization. Very severe aplastic anaemia, tetracycline-resistant Acinetobacter spp. BSI, and unresolved neutropenia after infection were closely associated with 30-day mortality. Non-survivors often presented with higher median PCT and CRP levels and severe complications, such as intracranial infection, cardiac dysfunction, respiratory failure, and severe sepsis or septic shock. Our study also identified inappropriate empirical antibiotic therapy as an independent predictor of 30-day mortality (OR: 11.234, 95% CI: 1.261–20.086, P = 0.030). This study was the first to report A. oleivorans as a human pathogen, and to identify its unique oxacillinase, OXA-325. An environment-originated non-pathogenic species can become pathogenic when the body’s immunity is compromised. Our results also highlighted the importance of improving neutropenia after infection, treating severe organ dysfunction, and administering appropriate empirical antibiotic therapy to reduce mortality in this patient population.
Tài liệu tham khảo
Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of Acinetobacter Infections: a Century of Challenges[J]. Clin Microbiol Rev. 2017;30(1):409–47. https://doi.org/10.1128/CMR.00058-16.
Lee HY, Chen CL, Wu SR, et al. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients[J]. Crit Care Med. 2014;42(5):1081–8. https://doi.org/10.1097/CCM.0000000000000125.
Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream Infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States[J]. J Infect. 2012;64(3):282–90. https://doi.org/10.1016/j.jinf.2011.12.008.
Balkhair A, Al-Muharrmi Z, Al’adawi B, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend[J]. Int J Infect Dis. 2019;85:10–5. https://doi.org/10.1016/j.ijid.2019.05.004.
Freire MP, De Oliveira Garcia D, Garcia CP, et al. Bloodstream Infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia[J]. Clin Microbiol Infect. 2016;22(4):352–8. https://doi.org/10.1016/j.cmi.2015.12.010.
Tavares LCB, Cunha MPV, De Vasconcellos FM, et al. Genomic and clinical characterization of IMP-1-Producing multidrug-resistant Acinetobacter bereziniae isolates from Bloodstream Infections in a Brazilian Tertiary Hospital[J]. Microb Drug Resist. 2020;26(11):1399–404. https://doi.org/10.1089/mdr.2019.0210.
Baraka A, Traglia GM, Montana S, et al. An Acinetobacter Non-baumannii Population Study: Antimicrobial Resistance genes (ARGs)[J]. Antibiot (Basel). 2020;10(1). https://doi.org/10.3390/antibiotics10010016.
Fujikura Y, Yuki A, Hamamoto T, et al. Blood stream Infections caused by Acinetobacter baumannii group in Japan - Epidemiological and clinical investigation[J]. J Infect Chemother. 2016;22(6):366–71. https://doi.org/10.1016/j.jiac.2016.02.006.
Kishii K, Kikuchi K, Yoshida A, et al. Antimicrobial susceptibility profile of Acinetobacter species isolated from blood cultures in two Japanese university hospitals[J]. Microbiol Immunol. 2014;58(2):142–6. https://doi.org/10.1111/1348-0421.12117.
Kiyasu Y, Hitomi S, Funayama Y, et al. Characteristics of invasive Acinetobacter Infection: a multicenter investigation with molecular identification of causative organisms[J]. J Infect Chemother. 2020;26(5):475–82. https://doi.org/10.1016/j.jiac.2019.12.010.
Chusri S, Chongsuvivatwong V, Rivera JI, et al. Clinical outcomes of hospital-acquired Infection with Acinetobacter nosocomialis and Acinetobacter pittii[J]. Antimicrob Agents Chemother. 2014;58(7):4172–9. https://doi.org/10.1128/AAC.02992-14.
Wang Q, Wang Z, Zhang F, et al. Long-term continuous Antimicrobial Resistance Surveillance among Nosocomial Gram-negative Bacilli in China from 2010 to 2018 (CMSS)[J]. Infect Drug Resist. 2020;13:2617–29. https://doi.org/10.2147/IDR.S253104.
Zhang L, Zhai W, Lin Q, et al. Carbapenem-resistant Enterobacteriaceae in hematological patients: outcome of patients with Carbapenem-resistant Enterobacteriaceae Infection and risk factors for progression to Infection after rectal colonization[J]. Int J Antimicrob Agents. 2019;54(4):527–9. https://doi.org/10.1016/j.ijantimicag.2019.06.023.
Shargian-Alon L, Gafter-Gvili A, Ben-Zvi H, et al. Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies - a retrospective study[J]. Leuk Lymphoma. 2019;60(11):2787–92. https://doi.org/10.1080/10428194.2019.1599113.
Wang X, Zhang L, Sun A, et al. Acinetobacter baumannii bacteraemia in patients with haematological malignancy: a multicentre retrospective study from the Infection Working Party of Jiangsu Society of Hematology[J]. Eur J Clin Microbiol Infect Dis. 2017;36(7):1073–81. https://doi.org/10.1007/s10096-016-2895-2.
Xu C, Lin Q, Zhao Y, et al. Clinical characteristics and risk factors of Aeromonas bloodstream Infections in patients with hematological diseases[J]. BMC Infect Dis. 2022;22(1):303. https://doi.org/10.1186/s12879-022-07277-7.
Zhao Y, Lin Q, Liu L, et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in adult patients with Acute Leukemia[J]. Clin Infect Dis. 2020;71(Suppl 4):386–S393. https://doi.org/10.1093/cid/ciaa1522.
Chiang DH, Wang CC, Kuo HY, et al. Risk factors for mortality in patients with Acinetobacter baumannii bloodstream Infection with genotypic species identification[J]. J Microbiol Immunol Infect. 2008;41(5):397–402.
Rinke C, Chuvochina M, Mussig AJ, et al. A standardized archaeal taxonomy for the genome taxonomy Database[J]. Nat Microbiol. 2021;6(7):946–59. https://doi.org/10.1038/s41564-021-00918-8.
Haber LT, Dourson ML, Allen BC, et al. Benchmark dose (BMD) modeling: current practice, issues, and challenges[J]. Crit Rev Toxicol. 2018;48(5):387–415. https://doi.org/10.1080/10408444.2018.1430121.
Leao AC, Menezes PR, Oliveira MS, et al. Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis[J]. BMC Infect Dis. 2016;16:386. https://doi.org/10.1186/s12879-016-1695-8.
Zilberberg MD, Nathanson BH, Sulham K, et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii Pneumonia and sepsis[J]. Crit Care. 2016;20(1):221. https://doi.org/10.1186/s13054-016-1392-4.
Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial Infections[J]. Chest. 2020;158(3):929–38. https://doi.org/10.1016/j.chest.2020.03.087.
Choi SH, Cho EB, Chung JW, et al. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center[J]. J Infect Chemother. 2019;25(1):6–11. https://doi.org/10.1016/j.jiac.2018.09.011.
Ozvatan T, Akalin H, Sinirtas M, et al. Nosocomial Acinetobacter Pneumonia: treatment and prognostic factors in 356 cases[J]. Respirology. 2016;21(2):363–9. https://doi.org/10.1111/resp.12698.
Visca P, Seifert H, Towner KJ. Acinetobacter Infection–an emerging threat to human health[J]. IUBMB Life. 2011;63(12):1048–54. https://doi.org/10.1002/iub.534.
Sader HS, Flamm RK, Jones RN. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)[J]. Diagn Microbiol Infect Dis. 2013;76(2):217–21. https://doi.org/10.1016/j.diagmicrobio.2013.02.009.
Guan X, He L, Hu B, et al. Laboratory diagnosis, clinical management and Infection control of the Infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement[J]. Clin Microbiol Infect. 2016;22:15–S25. https://doi.org/10.1016/j.cmi.2015.11.004.
Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort[J]. J Antimicrob Chemother. 2014;69(11):3119–26. https://doi.org/10.1093/jac/dku233.
Batirel A, Balkan, Ii, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections[J]. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311–22. https://doi.org/10.1007/s10096-014-2070-6.
Nazer LH, Kharabsheh A, Rimawi D, et al. Characteristics and outcomes of Acinetobacter baumannii Infections in critically Ill patients with Cancer: a matched case-control Study[J]. Microb Drug Resist. 2015;21(5):556–61. https://doi.org/10.1089/mdr.2015.0032.
Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia[J]. J Microbiol Immunol Infect. 2012;45(5):356–62. https://doi.org/10.1016/j.jmii.2011.12.009.
Henig O, Weber G, Hoshen MB, et al. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and Infection: matched case-control study[J]. Eur J Clin Microbiol Infect Dis. 2015;34(10):2063–8. https://doi.org/10.1007/s10096-015-2452-4.
Routsi C, Pratikaki M, Platsouka E, et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes[J]. Infection. 2010;38(3):173–80. https://doi.org/10.1007/s15010-010-0008-1.
Kannian P, Mahanathi P, Ashwini V, et al. Carbapenem-Resistant Gram negative Bacilli are predominantly multidrug or pan-drug Resistant[J]. Microb Drug Resist. 2021;27(8):1057–62. https://doi.org/10.1089/mdr.2020.0294.
Kumar A, Randhawa VS, Nirupam N, et al. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream Infections in a neonatal intensive care unit, Delhi, India[J]. J Infect Dev Ctries. 2014;8(8):1049–54. https://doi.org/10.3855/jidc.4248.
Lee JY, Kang CI, Ko JH, et al. Clinical features and risk factors for development of breakthrough gram-negative bacteremia during Carbapenem Therapy[J]. Antimicrob Agents Chemother. 2016;60(11):6673–8. https://doi.org/10.1128/AAC.00984-16.
Jang TN, Lee SH, Huang CH, et al. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream Infections in the adult intensive care unit: a case-control study[J]. J Hosp Infect. 2009;73(2):143–50. https://doi.org/10.1016/j.jhin.2009.06.007.
Arvaniti K, Lathyris D, Ruimy R, et al. The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit[J]. Crit Care. 2012;16(3):R102. https://doi.org/10.1186/cc11383.
Toh BE, Paterson DL, Kamolvit W, et al. Species identification within Acinetobacter calcoaceticus-baumannii complex using MALDI-TOF MS[J]. J Microbiol Methods. 2015;118:128–32. https://doi.org/10.1016/j.mimet.2015.09.006.
Kang YS, Jung J, Jeon CO, et al. Acinetobacter oleivorans sp. nov. is capable of adhering to and growing on diesel-oil[J]. J Microbiol. 2011;49(1):29–34. https://doi.org/10.1007/s12275-011-0315-y.
Kamolvit W, Sidjabat HE, Paterson DL. Molecular Epidemiology and mechanisms of Carbapenem Resistance of Acinetobacter spp. in Asia and Oceania[J]. Microb Drug Resist. 2015;21(4):424–34. https://doi.org/10.1089/mdr.2014.0234.